View in EDS HTML Full Text PDF Full Text

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.

Saved in:
Bibliographic Details
Title: Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
Authors: Burger, Jan A.1 (AUTHOR), Robak, Tadeusz2 (AUTHOR), Demirkan, Fatih3 (AUTHOR), Bairey, Osnat4 (AUTHOR), Moreno, Carol5 (AUTHOR), Simpson, David6 (AUTHOR), Munir, Talha7 (AUTHOR), Stevens, Don A.8 (AUTHOR), Dai, Sandra9 (AUTHOR), Cheung, Leo W. K.9 (AUTHOR), Kwei, Kevin9 (AUTHOR), Lal, Indu9 (AUTHOR), Hsu, Emily9 (AUTHOR), Kipps, Thomas J.10 (AUTHOR), Tedeschi, Alessandra11 (AUTHOR)
Source: Leukemia & Lymphoma. Jun2022, Vol. 63 Issue 6, p1375-1386. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 157176988
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Burger%2C+Jan+A%2E%22">Burger, Jan A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Robak%2C+Tadeusz%22">Robak, Tadeusz</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Demirkan%2C+Fatih%22">Demirkan, Fatih</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bairey%2C+Osnat%22">Bairey, Osnat</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moreno%2C+Carol%22">Moreno, Carol</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Simpson%2C+David%22">Simpson, David</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Munir%2C+Talha%22">Munir, Talha</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stevens%2C+Don+A%2E%22">Stevens, Don A.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dai%2C+Sandra%22">Dai, Sandra</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cheung%2C+Leo+W%2E+K%2E%22">Cheung, Leo W. K.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kwei%2C+Kevin%22">Kwei, Kevin</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lal%2C+Indu%22">Lal, Indu</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hsu%2C+Emily%22">Hsu, Emily</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kipps%2C+Thomas+J%2E%22">Kipps, Thomas J.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tedeschi%2C+Alessandra%22">Tedeschi, Alessandra</searchLink><relatesTo>11</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Leukemia+%26+Lymphoma%22">Leukemia & Lymphoma</searchLink>. Jun2022, Vol. 63 Issue 6, p1375-1386. 12p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=157176988
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2021.2020779
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 1375
    Titles:
      – TitleFull: Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Burger, Jan A.
      – PersonEntity:
          Name:
            NameFull: Robak, Tadeusz
      – PersonEntity:
          Name:
            NameFull: Demirkan, Fatih
      – PersonEntity:
          Name:
            NameFull: Bairey, Osnat
      – PersonEntity:
          Name:
            NameFull: Moreno, Carol
      – PersonEntity:
          Name:
            NameFull: Simpson, David
      – PersonEntity:
          Name:
            NameFull: Munir, Talha
      – PersonEntity:
          Name:
            NameFull: Stevens, Don A.
      – PersonEntity:
          Name:
            NameFull: Dai, Sandra
      – PersonEntity:
          Name:
            NameFull: Cheung, Leo W. K.
      – PersonEntity:
          Name:
            NameFull: Kwei, Kevin
      – PersonEntity:
          Name:
            NameFull: Lal, Indu
      – PersonEntity:
          Name:
            NameFull: Hsu, Emily
      – PersonEntity:
          Name:
            NameFull: Kipps, Thomas J.
      – PersonEntity:
          Name:
            NameFull: Tedeschi, Alessandra
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: Jun2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 10428194
          Numbering:
            – Type: volume
              Value: 63
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Leukemia & Lymphoma
              Type: main
ResultId 1